Literature DB >> 16840715

Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice.

Brian J Bennett1, Marta Scatena, Elizabeth A Kirk, Marcello Rattazzi, Rebecca M Varon, Michelle Averill, Stephen M Schwartz, Cecilia M Giachelli, Michael E Rosenfeld.   

Abstract

OBJECTIVE: Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) superfamily of proteins, plays an important role in bone remodeling and is expressed in both mouse and human atherosclerotic lesions. The current study was designed to assess whether OPG plays a role in the progression and calcification of advanced atherosclerotic lesions in apoE(-/-) mice. METHODS AND
RESULTS: Atherosclerotic lesion area and composition and aortic calcium content were examined in mice deficient in both OPG and apolipoprotein E (OPG(-/-).apoE(-/-) mice) at 20, 40, and 60 weeks of age. Littermate OPG(+/+).apoE(-/-) mice were used as controls. The average cross-sectional area of lesions in the innominate arteries was increased in OPG(-/-).apoE(-/-) mice at 40 and 60 weeks of age. The increase in lesion area was coupled with a reduced cellularity and an increase in connective tissue including laminated layers of elastin. Sixty-week-old OPG(-/-).apoE(-/-) mice also had an increase in the area of calcification of the lesions. There were no differences in markers of plaque stability. In vitro, OPG induced matrix metalloproteinase-9 (MMP-9) activity in macrophages and smooth muscle cells and acted as a survival factor for serum-deprived smooth muscle cells.
CONCLUSIONS: OPG inhibits advanced plaque progression by preventing an increase in lesion size and lesion calcification. OPG may act as a survival factor and may modulate MMP9 production in vascular cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840715     DOI: 10.1161/01.ATV.0000236428.91125.e6

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  105 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 2.  Emerging role of circulating calcifying cells in the bone-vascular axis.

Authors:  Gian Paolo Fadini; Marcello Rattazzi; Tomoyuki Matsumoto; Takayuki Asahara; Sundeep Khosla
Journal:  Circulation       Date:  2012-06-05       Impact factor: 29.690

3.  Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification.

Authors:  Yong Sun; Chang Hyun Byon; Kaiyu Yuan; Jianfeng Chen; Xia Mao; Jack M Heath; Amjad Javed; Kui Zhang; Peter G Anderson; Yabing Chen
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

4.  Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Authors:  Amit Noheria; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2010-03-25       Impact factor: 2.689

5.  Effect of Qingre Quyu Granule (清热祛瘀颗粒) on stabilizing plaques in the brachiocephalic artery of apolipoprotein E deficient mice.

Authors:  Yong Wang; Wen-li Cheng; Yuan-nan Ke; Zhe Cai; Li Chen; Yuan Xi; Pu Wang; Jian Guo; Hong Li; Cong-xin Huang
Journal:  Chin J Integr Med       Date:  2010-09-25       Impact factor: 1.978

Review 6.  Vascular calcification: pathobiology of a multifaceted disease.

Authors:  Linda L Demer; Yin Tintut
Journal:  Circulation       Date:  2008-06-03       Impact factor: 29.690

7.  Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 8.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

Review 9.  Vascular calcification: an update on mechanisms and challenges in treatment.

Authors:  Meiting Wu; Cameron Rementer; Cecilia M Giachelli
Journal:  Calcif Tissue Int       Date:  2013-03-01       Impact factor: 4.333

10.  Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells.

Authors:  Kristen A Johnson; Monika Polewski; Robert A Terkeltaub
Journal:  Circ Res       Date:  2008-01-17       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.